Phreesia, Inc.

Listed Company

PHRCIK 0001412408NYSELarge AcceleratedServices-Business Services, NecDelawareFY ends Jan 31

Period

FY 2026

Revenue

$480.59M

Net Income

$2.31M

Total Assets

$663.79M

Equity

$337.21M

Shares Out

61.81M

Op. Cash Flow

$78.81M

PHR$10.70−58.75% · past yearDBEQ Basic

Daily closing prices

Business

Phreesia, Inc. provides an integrated software, payments, and engagement platform addressing access to care, affordability, and patient health outcomes in healthcare delivery. The company offers subscription services, payment solutions (including processing and financing), and Network Solutions for life sciences companies to engage patients and providers. Phreesia serves ambulatory practices, health systems, hospitals, and life sciences organizations across the United States, facilitating approximately 180 million patient visits annually.

Summary from 10-K filed 2026-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2026 2026-01-31	FY 2025 2025-01-31	FY 2024 2024-01-31	FY 2023 2023-01-31	FY 2022 2022-01-31
Total revenues	481	420	356	281	213
Cost of revenue (excluding depreciation and amortization)	71	66	61	59	43
Payment solutions expense	83	69	63	50	39
Sales and marketing	100	121	147	151	106
Research and development	121	117	112	91	52
General and administrative	80	77	80	80	69
Depreciation	13	14	18	18	15
Amortization	18	14	12	7	6
Total expenses	487	478	493	457	330
Operating loss	−7	−58	−136	−177	−117
Other income, net	3	2	44,000	−175,000	−78,000
Loss on extinguishment of debt	−501,000	0	−1	0	0
Interest expense	−7	−2	−2	—	—
Interest income	2	3	4	—	—
Total other (expense) income, net	−2	2	1	889,000	−1
Loss before income tax expense	−9	−56	−135	−176	−118
Income tax benefit (expense)	11	−3	−2	−483,000	−182,000
Net income (loss)	2	−59	−137	−176	−118
Net income (loss) per share attributable to common stockholders - basic (in dollars per share)	0.04	−1.02	−2.51	−3.36	−2.37
Net income (loss) per share attributable to common stockholders - diluted (in dollars per share)	0.04	−1.02	−2.51	−3.36	−2.37
Weighted-average common shares outstanding - basic (in shares)	60	58	55	52	50
Weighted-average common shares outstanding - diluted (in shares)	61	58	55	52	50

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2026 2026-01-31	FY 2025 2025-01-31	FY 2024 2024-01-31	FY 2023 2023-09-30	FY 2023 2023-01-31
Cash, cash equivalents, and restricted cash (including restricted cash of $1,691)	74	84	88	—	177
Settlement assets	33	29	28	—	23
Accounts receivable, net of allowance for doubtful accounts of $1,523 and $1,468 as of January 31, 2026 and 2025, respectively	97	74	65	—	51
Cardholder receivables	38	0	—	—	—
Deferred purchase price receivables	18	0	—	—	—
Accrued interest and fees receivables	840,000	0	—	—	—
Deferred contract acquisition costs	410,000	401,000	768,000	—	1
Prepaid expenses and other current assets	18	16	14	—	11
Total current assets	280	203	196	—	262
Property and equipment, net of accumulated depreciation and amortization of $94,193 and $84,505 as of January 31, 2026 and 2025, respectively	20	24	17	—	22
Capitalized internal-use software, net of accumulated amortization of $69,390 and $55,991 as of January 31, 2026 and 2025, respectively	54	53	46	—	35
Operating lease right-of-use assets	2	1	266,000	—	569,000
Deferred contract acquisition costs	338,000	583,000	986,000	—	2
Intangible assets, net of accumulated amortization of $13,489 and $8,407 as of January 31, 2026 and 2025, respectively	80	28	32	—	11
Goodwill	170	76	76	42	34
Deferred tax assets	2	0	0	—	81,000
Other assets	2	3	3	—	3
Long-term cardholder receivables	48	0	—	—	—
Long-term deferred purchase price receivables	5	0	—	—	—
Total Assets	664	388	370	—	370
Settlement obligations	33	29	28	—	23
Current portion of debt and finance lease liabilities	8	8	6	—	5
Current portion of operating lease liabilities	1	964,000	393,000	—	934,000
Accounts payable	11	6	8	—	11
Accrued expenses	41	37	37	—	22
Due to healthcare providers	38	0	—	—	—
Deferred revenue	50	33	24	—	18
Other current liabilities	705,000	0	6	—	0
Total current liabilities	183	114	110	—	79
Long-term debt and finance lease liabilities	92	8	5	—	3
Operating lease liabilities, non-current	1	646,000	134,000	—	349,000
Long-term due to healthcare providers	45	0	—	—	—
Long-term deferred revenue	244,000	119,000	97,000	—	125,000
Long-term deferred tax liabilities	4	484,000	270,000	—	0
Other long-term liabilities	47,000	185,000	3	—	0
Total Liabilities	327	124	119	—	82
Commitments and contingencies (Note 11)	—	—	—	—	—
Preferred stock, undesignated, $0.01 par value$20,000,000 shares authorized as of both January 31, 2026 and 2025; no shares issued or outstanding as of January 31, 2026 and 2025, respectively	0	0	0	—	0
Common stock, $0.01 par value500,000,000 shares authorized as of both January 31, 2026 and 2025; 62,020,186 and 60,083,444 shares issued as of January 31, 2026 and 2025, respectively	620,000	601,000	577,000	—	542,000
Additional paid-in capital	1,182	1,111	1,039	—	927
Accumulated deficit	−799	−801	−743	—	−606
Accumulated other comprehensive loss	−382,000	−51,000	0	—	—
Treasury stock, at cost, 1,355,169 shares as of both January 31, 2026 and 2025	−46	−46	−46	—	−34
Total Stockholders Equity	337	265	251	—	288
Total Liabilities and Stockholders Equity	664	388	370	—	370

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2026 2026-01-31	FY 2025 2025-01-31	FY 2024 2024-01-31	FY 2023 2023-01-31	FY 2022 2022-01-31
Depreciation and amortization	31	28	29	25	21
Stock-based compensation expense	67	67	72	59	36
Amortization of deferred financing costs and debt discount	3	236,000	321,000	310,000	288,000
Non-cash gain on settlement	0	−2	0	0	—
Cost of Phreesia hardware purchased by customers	1	2	2	2	672,000
Deferred contract acquisition costs amortization	570,000	2	1	2	2
Non-cash operating lease expense	914,000	747,000	702,000	2	1
Deferred taxes	−13	214,000	228,000	434,000	143,000
Gains and losses for fair value option	−1	0	0	—	—
Accounts receivable	−23	−9	−11	−11	−10
Collections of principal on receivables originally held for sale to securitization	14	0	0	—	—
Accrued Interest Receivable	−446,000	0	0	—	—
Prepaid expenses and other assets	−1	−1	−2	250,000	−7
Deferred contract acquisition costs	−334,000	−1	0	−427,000	−3
Accounts payable	5	−3	−2	5	3
Accrued expenses and other liabilities	3	182,000	14	3	−3
Payment of due to provider for receivables originally held for sale to securitization	−18	0	0	—	—
Lease liabilities	−1	−824,000	−1	−1	−1
Deferred revenue	8	9	731,000	1	3
Net cash provided by (used in) operating activities	79	32	−32	−90	−75
Collections of cardholder receivables held for investment and deferred purchase price	16	0	0	—	—
Acquisitions, net of cash acquired	−153	0	−15	0	−34
Capitalized internal-use software	−13	−15	−19	−21	−12
Purchases of property and equipment	−11	−9	−6	−5	−18
Net cash used in investing activities	−162	−24	−40	−26	−65
Proceeds from issuance of common stock upon exercise of stock options	1	1	955,000	2	5
Treasury stock to satisfy tax withholdings on stock compensation awards	0	0	−12	−19	−9
Proceeds from employee stock purchase plan	2	3	3	3	2
Finance lease payments	−7	−8	−7	−6	−4
Constructive financing	0	0	2	0	0
Principal payments on financing agreements	−1	−1	−600,000	−216,000	−1
Debt issuance costs and loan facility fee payments	−3	−152,000	−1	−397,000	−125,000
Financing payments of acquisition-related liabilities	0	−6	−1	0	−3
Debt extinguishment costs	0	0	−758,000	0	0
Proceeds from debt instruments	110	0	0	—	0
Principal payments on debt instruments	−20	0	0	—	—
Payments due to provider for unfunded receivables	−10	0	0	—	—
Net cash provided by (used in) financing activities	73	−11	−17	−21	235
Effect of exchange rate changes on cash, cash equivalents and restricted cash	−176,000	−106,000	0	0	—
Net decrease in cash, cash equivalents and restricted cash	−10	−3	−89	−137	95
Non-cash activity related to credit card receivables and deferred purchase price	18	0	0	—	—
Right of use assets acquired in exchange for operating lease liabilities	0	2	398,000	0	81,000
Property and equipment acquisitions through finance leases	0	14	7	526,000	7
Purchase of property and equipment and capitalized software included in accounts payable and accrued liabilities	2	2	1	2	1
Capitalized stock-based compensation	1	1	1	1	489,000
Issuance of stock to settle liabilities for stock-based compensation	13	12	12	12	0
Deferred consideration liabilities payable in business combinations	0	0	9	0	0
Issuance of stock as consideration in business combinations	0	0	35	0	0
Capitalized software acquired through vendor financing	0	0	2	0	0
Interest	2	2	1	763,000	802,000
Income taxes	2	3	37,000	39,000	49,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Phreesia, Inc.'s CIK number?

Phreesia, Inc.'s SEC CIK number is 0001412408 (1412408). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Phreesia, Inc.'s SEC filings?

All of Phreesia, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Phreesia, Inc. last report earnings?

Phreesia, Inc. (PHR) most recently filed an earnings 8-K with the SEC on May 27, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001412408-26-000166). This is Phreesia, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Phreesia, Inc.'s most recent earnings 8-K?

Phreesia, Inc.'s latest earnings 8-K (Item 2.02) was filed May 27, 2026 under accession 0001412408-26-000166. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Phreesia, Inc.'s latest earnings 8-K →
Look up any company's CIK number →